Author's response to reviews

Title: Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report

Authors:

Dae Won Kim (dkim4@mdanderson.org)
Edelyn Barcena (ebarcena@broncs.utpa.edu)
Urvi N Mehta (unmehta@mdanderson.org)
Michell L Rohlfs (mrohlfs@mdanderson.org)
Ashok J Kumar (akumar@mdanderson.org)
Marta Penas-Prado (mpenaspr@mdanderson.org)
Kevin B Kim (kimkb@sutterhealth.org)

Version: 3
Date: 21 March 2015

Author's response to reviews:

Dear Editor

We greatly appreciate the reviewers’ thoughtful comments which helped improve the manuscript. We have been addressed accordingly in a revised manuscript. In the following, we give a point by point reply to the comments.

Reviewer 1

1) In the background add the reference of Lombardi G et al, Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches, 2011, Oncologist

We added the reference.

2) Change pia matter with pia mather in the background

We fixed it.

3) IN the case presentation explain if the patient performed a CT before or after lymph node dissection

We explained it in the case presentation.

4) You wrote that BRAF molecular analysis was performed but you did not explain on which metastatic lesion (lung? peritoneum?)

BRAF test was performed with his primary melanoma.

5) Explain the toxicity of vemurafenib and dabrafenib according to CTCAE Schedule.
We did not record the actual grade of the toxicity since it was not a clinical trial. Therefore, we described the toxicity in more generic term.

6) Explain the biological mechanism of dabrafenib and trametinib

We explained the mechanism of dabrafenib and trametinib.

7) In the discussion section explain better the role of radiation therapy for brain metastases writing that the new molecular drugs can be used before a radiation therapy having a good activity in this setting of patients.

We added it in the discussion.

8) Needs some language corrections before being published.

Our manuscript has been edited by a native-English speaker with scientific expertise.

Reviewer 2.

Kim et al. report the clinical history of a patient suffering from BRAF mutant melanoma, which spread multiple metastases involving the leptomeninx and the brain. The authors comprehensively described the response of all metastatic lesions against different therapeutic treatments. They observed a stable response of the leptomeningeal and parenchymal brain lesions to a combined targeted-therapy against BRAF. Finally, the authors critically discussed their observations.

It is a well written case report with clinical significance.

We appreciate the valuable comments.

Sincerely

Dae Won Kim, MD

Melanoma Medical Oncology Fellow

Department of Melanoma Medical Oncology

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA